Recent 8-K filings for TBPH
Highest-materiality recent filing
Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones
- YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
- TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.
-
Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled
YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).
-
Theravance settles YUPELRI patent suit; generic license start April 23, 2039
Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.
-
Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.
-
Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review
Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.
-
Management team conducting one-on-one meetings with analysts and investors in San Francisco from Jan 12-15, 2026.
-
Theravance holds ampreloxetine KOL event; AGM set for June 12, 2026
Virtual KOL investor event for ampreloxetine held Dec. 8, 2025; slide deck furnished as exhibit.
-
YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).
-
Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.
-
Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039
Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.
-
Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%
YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.
-
Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered
China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.
-
Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039
Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).
-
Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M
Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.
-
Shareholders elected Rick E. Winningham, Jeremy T. Grant, Susannah Gray, Donal O'Connor as Class II directors.
-
Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M
YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.
-
YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
-
Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).
-
Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039
Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.
-
Management team to participate in fireside chat and one-on-one meetings at H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
-
Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed
Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.
-
Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M
Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
-
Theravance Biopharma shareholders elect three Class I directors, ratify EY, approve say-on-pay
Elected Eran Broshy, James Kelly, Laurie Smaldone Alsup as Class I directors for three-year terms; votes for each exceeded 35 million.
-
Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039
Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.70 · Most common event earnings